Monday 3rd September 2018
|Text too small?|
Fisher & Paykel Healthcare expects the cost of contesting the latest patent allegations from rival ResMed will cut annual earnings by as much as $10 million in a far-ranging dispute across multiple jurisdictions.
The Auckland-based maker of hospital equipment and personal sleep apnoea products will contest complaints in the US International Trade Commission (ITC) and US District Court for the Southern District of California, it said in a statement. F&P Healthcare cut forecast profit to $205 million to $210 million in the year ending March 31 from a previous forecast of $215 million due to the cost of defending the litigation.
"Fisher & Paykel Healthcare respects the valid intellectual property rights of others, and we are confident in our position with respect to ResMed’s patents given the rigorous clearance we conduct before any product is released to market," managing director Lewis Gradon said. "We are well prepared to vigorously contest these claims."
ResMed filed a petition in the ITC seeking to ban the importation and sale of F&P Healthcare's Simplus full face mask, Eson nasal mask and Eson 2 nasal mask in the US, and separately lodged a new suit in the US district court accusing the Kiwi firm of patent infringement and seeking damages plus an injunction against future sales of the masks. The New York Stock Exchange-listed company withdrew a complaint to the US ITC last year, saying at the time it still planned to file a new action.
“ResMed provides millions of consumers with high-quality products, which are the direct result of substantial and sustained investments in research and development, as well as a focus on each consumer’s therapy needs,” ResMed global general counsel and chief administrative officer David Pendarvis said in a separate statement. “We will defend our intellectual property wherever necessary to ensure that patients worldwide continue to receive the high-quality care they deserve, and are confident that when the ITC and the district court hear all the evidence, ResMed will prevail in these cases."
F&P Healthcare's profit warning comes little over a week after the company raised its full-year earnings forecast by about $5 million as a weak New Zealand dollar increased the value of overseas sales.
The companies have been locked in litigation since 2016 spanning the US, UK, Europe, New Zealand and Australia. F&P Healthcare spent $15.6 million on litigation in the year ended March 31, 2018, down from $20.7 million a year earlier. It had previously signaled those costs would be a similar level in the 2019 financial year.
F&P Healthcare shares last traded at $16.39, and have gained 14 percent so far this year.
No comments yet
MARKET CLOSE: NZ shares dip as global trade jitters weigh on A2, F&P
NZ dollar set for weekly gain after Reserve Bank surprise
Burger Fuel exploring sale after review questions listing merits
New net migration data to remain rubbery for quite some time
NZX to push sales this year after reshaping business dents 2018 profit
Slowing new orders growth weighs on January PMI
New NZ dry dock a basis for new industry - KiwiRail
Wellington Drive beats 2H sales forecast, will meet earnings guidance
NZIQS decides more training is the answer to past president's misconduct
February 15th Morning Report